Video Hero Poster

Enhancing critical medicines

Learn More

ADVANZ PHARMA is a specialty pharmaceutical company with a strategic focus on complex medicines in Europe that is committed to improving the lives of patients by enhancing the critical medicines they depend on.

We could not do this without the resilience and entrepreneurial spirit of our people, the successful collaboration with our partners, and intrinsic guidance of our values to help us achieve our purpose while becoming a truly dynamic, progressive company in the process.

Our portfolio —

At ADVANZ PHARMA, our European hospital portfolio of complex medicines focuses on Anti-infectives, Endocrinology and Critical Care medicines.

This is bolstered by an established brands business unit of more than 180 molecules sold into 100 countries across a wide range of therapy areas such as CVD, pain management, ophthalmology, urology, and central nervous system disorders.

Careers & Culture —

The success of any company is driven by its people. We are no different. Our teams are made up of people who come from all walks of life and backgrounds, and thrive in an environment where diversity is celebrated but where we are all united by the same passion, to help improve the lives of patients by enhancing the critical medicines they depend on.

Responsibility —

ADVANZ PHARMA is committed to improving the lives of patients by enhancing the critical medicines they depend on. Partnerships are a fundamental part of this, and is vital to creating new, lasting relationships, where we can continue to invest significantly in products to help broaden patient access and health outcomes.

Our Partnerships —

ADVANZ PHARMA is committed to improving the lives of patients by enhancing the critical medicines they depend on. Partnerships are a fundamental part of this, and is vital to creating new, lasting relationships, where we can continue to invest significantly in products to help broaden patient access and health outcomes.

Investors —

Our goal is clear – to become the go to partner when commercialising complex medicines in European hospitals

We will do this by investing significantly in our portfolio through a combination of pipeline development and acquisition.

Latest News —

Image for Cidron Aida Finco S.à r.l.  Successful pricing of €175.0 million 5% Senior Secured Notes due 2028

Press Releases — 20 Jan 2022

Cidron Aida Finco S.à r.l. Successful pricing of €175.0 million 5% Senior Secured Notes due 2028

Learn more
Image for Cidron Aida Finco S.à r.l. Proposed Offering of €150 million 5% Senior Secured Notes due 2028

Press Releases — 17 Jan 2022

Cidron Aida Finco S.à r.l. Proposed Offering of €150 million 5% Senior Secured Notes due 2028

Learn more
Image for Allecra Therapeutics and ADVANZ PHARMA Sign Exclusive License and Supply Agreement for Allecra’s Antibiotic Cefepime/enmetazobactam in Europe

Allecra Therapeutics and ADVANZ PHARMA Sign Exclusive License and Supply Agreement for Allecra’s Antibiotic Cefepime/enmetazobactam in Europe

Learn more
Image for ADVANZ PHARMA launches its first Environmental, Social and Governance report

ADVANZ PHARMA launches its first Environmental, Social and Governance report

Learn more
Image for ADVANZ PHARMA makes key changes to senior leadership to further accelerate next phase of growth

Press Releases — 18 Nov 2021

ADVANZ PHARMA makes key changes to senior leadership to further accelerate next phase of growth

Learn more
Image for ADVANZ PHARMA announces launch of MYRELEZ® in Norway, the first generic lanreotide for the treatment of acromegaly and gastroenteropancreatic neuroendocrine tumours (GEP-NETs)

Press Releases — 11 Nov 2021

ADVANZ PHARMA announces launch of MYRELEZ® in Norway, the first generic lanreotide for the treatment of acromegaly and gastroenteropancreatic neuroendocrine tumours (GEP-NETs)

Learn more